Compare IMUX & FOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMUX | FOA |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | United States | United States |
| Employees | 66 | 784 |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 188.8M | 177.1M |
| IPO Year | 2013 | N/A |
| Metric | IMUX | FOA |
|---|---|---|
| Price | $14.17 | $20.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $36.00 | $26.00 |
| AVG Volume (30 Days) | ★ 232.3K | 40.6K |
| Earning Date | 05-14-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $0.58 |
| Revenue Next Year | N/A | $6.91 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.51 | $15.77 |
| 52 Week High | $15.77 | $29.58 |
| Indicator | IMUX | FOA |
|---|---|---|
| Relative Strength Index (RSI) | 62.56 | 54.17 |
| Support Level | $0.74 | $18.65 |
| Resistance Level | $15.77 | $23.51 |
| Average True Range (ATR) | 1.18 | 0.78 |
| MACD | -0.21 | 0.06 |
| Stochastic Oscillator | 69.09 | 69.50 |
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
Finance of America Companies Inc provides home equity-based financing solutions for modern retirement and offers capital markets and portfolio management capabilities to optimize loan distribution to investors. The Company operates through two segments: Retirement Solutions and Portfolio Management. The Retirement Solutions segment handles loan origination, including HECM and non-agency reverse mortgage loans, generating revenue from origination fees and initial gains, with loans transferred to the Portfolio Management segment. The Portfolio Management segment, which generates the majority of revenue, provides securitization, loan sales, risk management, and asset management services, and earns revenue from net interest income, fair value changes, and servicing-related income.